Atrium Therapeutics (RNA) investor relations material

Company overview and strategic focus

• Formed from a spin-out following the Avidity-Novartis transaction, focusing on pioneering RNA therapeutics for cardiac diseases.

• Four programs are in development, with lead assets targeting rare genetic cardiomyopathies.

• Collaborations with Eli Lilly and Bristol Myers Squibb (BMS) were assumed in the spin-out.

• The company leverages an antibody-oligonucleotide conjugate (AOC) platform for targeted siRNA delivery to the heart.

• Recent BMS collaboration milestones brought in $30 million, with potential for up to $2.2 billion in future milestones and royalties.

Lead programs and clinical development

• The lead program targets PRKAG2 syndrome, a severe, early-onset genetic cardiomyopathy with high unmet need.

• Phase I/II Corventis study uses adaptive, open-label design with flat dosing (40–160 mg), focusing on safety, tissue uptake, and mRNA knockdown.

• Initial proof-of-concept data expected in the second half of next year, with long-term extension planned.

• Secondary program targets PLN cardiomyopathy, with IND filing planned for 2027.

• Both programs aim for significant knockdown of disease targets, with animal models showing strong efficacy at moderate knockdown levels.

Market opportunity and patient identification

• PRKAG2 syndrome and PLN cardiomyopathy are both underdiagnosed due to low rates of genetic testing.

• Literature estimates 1,000–2,000 for PRKAG2 and 2,000–4,000 for PLN in the US, but actual prevalence may be higher.

• Ongoing efforts with labs and advocacy groups aim to better define and expand the identified patient population.

• The company anticipates broader indication expansion opportunities for both lead programs.

• Increased interest and activity in the genetic cardiomyopathy space are expected to drive higher diagnosis rates.